---
title: Decrypting lysine deacetylase inhibitor action and protein modifications by
  dose-resolved proteomics
date: '2024-05-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38795348/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240526182221&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Lysine deacetylase inhibitors (KDACis) are approved drugs for cutaneous
  T cell lymphoma (CTCL), peripheral T cell lymphoma (PTCL), and multiple myeloma,
  but many aspects of their cellular mechanism of action (MoA) and substantial toxicity
  are not well understood. To shed more light on how KDACis elicit cellular responses,
  we systematically measured dose-dependent changes in acetylation, phosphorylation,
  and protein expression in response to 21 clinical and pre-clinical KDACis. The ...
disable_comments: true
---
Lysine deacetylase inhibitors (KDACis) are approved drugs for cutaneous T cell lymphoma (CTCL), peripheral T cell lymphoma (PTCL), and multiple myeloma, but many aspects of their cellular mechanism of action (MoA) and substantial toxicity are not well understood. To shed more light on how KDACis elicit cellular responses, we systematically measured dose-dependent changes in acetylation, phosphorylation, and protein expression in response to 21 clinical and pre-clinical KDACis. The ...